Immuron Ltd ADR (NASDAQ:IMRN) — Market Cap & Net Worth
Market Cap & Net Worth: Immuron Ltd ADR (IMRN)
Immuron Ltd ADR (NASDAQ:IMRN) has a market capitalization of $6.45 Million ($6.45 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28158 globally and #5791 in its home market, demonstrating a 6.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immuron Ltd ADR's stock price $0.88 by its total outstanding shares 8083022 (8.08 Million). Also see Immuron Ltd ADR balance sheet assets for a full breakdown of the balance sheet.
Immuron Ltd ADR Market Cap History: 2017 to 2026
Immuron Ltd ADR's market capitalization history from 2017 to 2026. Data shows change from $42.76 Million to $9.54 Million (-15.79% CAGR). Also see Immuron Ltd ADR (IMRN) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Immuron Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #809 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2606 of 3165 |
Weight: Immuron Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immuron Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immuron Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Immuron Ltd ADR (IMRN) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.85x
Immuron Ltd ADR's market cap is 0.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $42.76 Million | $1.40 Million | -$6.80 Million | 30.63x | N/A |
| 2018 | $46.88 Million | $1.84 Million | -$3.01 Million | 25.44x | N/A |
| 2019 | $29.34 Million | $2.39 Million | -$4.66 Million | 12.29x | N/A |
| 2020 | $51.49 Million | $2.52 Million | -$2.90 Million | 20.44x | N/A |
| 2021 | $20.21 Million | $145.78K | -$8.38 Million | 138.62x | N/A |
| 2022 | $16.81 Million | $765.19K | -$2.85 Million | 21.97x | N/A |
| 2023 | $15.16 Million | $1.80 Million | -$3.79 Million | 8.40x | N/A |
| 2024 | $13.74 Million | $4.90 Million | -$6.94 Million | 2.80x | N/A |
| 2025 | $6.16 Million | $7.29 Million | -$5.22 Million | 0.85x | N/A |
Competitor Companies of IMRN by Market Capitalization
Companies near Immuron Ltd ADR in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Immuron Ltd ADR to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Immuron Ltd ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Immuron Ltd ADR Historical Marketcap From 2017 to 2026
Between 2017 and today, Immuron Ltd ADR's market cap moved from $42.76 Million to $ 9.54 Million, with a yearly change of -15.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.54 Million | +54.75% |
| 2025 | $6.16 Million | -55.15% |
| 2024 | $13.74 Million | -9.33% |
| 2023 | $15.16 Million | -9.86% |
| 2022 | $16.81 Million | -16.80% |
| 2021 | $20.21 Million | -60.75% |
| 2020 | $51.49 Million | +75.48% |
| 2019 | $29.34 Million | -37.41% |
| 2018 | $46.88 Million | +9.64% |
| 2017 | $42.76 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Immuron Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.45 Million USD |
| MoneyControl | $6.45 Million USD |
| MarketWatch | $6.45 Million USD |
| marketcap.company | $6.45 Million USD |
| Reuters | $6.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more